Nearly three fourths of infants born during the 2023-2024 respiratory syncytial virus (RSV) season received protection with either nirsevimab or exposure to maternal RSVpreF, with maternal RSVpreF ...

The patents in contention are numbers 3,109,258, 2,222,710 and 3,178,490, all awarded by the European Patent Office and covering recombinant RSV antigens ... Pfizer's RSVpreF vaccine is in hot ...

The FDA gave Pfizer's RSVpreF (PF-06928316) vaccine the new status – which earns extra support from the FDA during clinical development and paves the way for a faster six-month review once a ...